



Press release

February 07, 2024

## **The LYSA is expanding with a commission in charge of chronic lymphocytic leukemia and Waldenström macroglobulinemia.**

***This development is the result of a collective desire of the FILO CLL/WM committee to unify French projects related to lymphoid malignancies and to conduct its next studies within LYSA/LYSARC.***

Historically in France, clinical research concerning lymphoid hematological diseases has been structured and developed on the one hand for non-Hodgkin's lymphomas and Hodgkin's disease within GELA and GOELAMS with the creation in 2012 of a single entity called the LYSA, and on the other hand for chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) within the French Cooperative Group of CLL and WM and GOELAMS which joined within the FILO group.

All these hematological diseases however share similar biological and clinical characteristics. The explosion of new therapies often common to these pathologies, the need to develop large-scale clinical and biological studies in this area in a context of increasing international competition, and the common interest of physicians treating these similar pathologies led us in February 2024 to join forces and for the FILO CLL/WM to join the LYSA within a new commission. This should make it possible to strengthen clinical research in this area with a view to further improving patient care.

*« The LYSA is pleased to announce the creation of a new scientific committee dedicated to CLL and WM! LYSA warmly welcomes all the French CLL/WM investigators who collectively decided to transition from FILO to LYSA for conducting their next studies and unifying French projects related to lymphoid malignancies. »* Franck Morschhauser, President of LYSA

### **About the LYSA-LYSARC:**

LYSA, The Lymphoma Study Association, is a non-profit, internationally leading, academic cooperative group gathering multidisciplinary expertise in lymphoma. Its operational structure, LYSARC, The Lymphoma Academic Research Organization, has all the integrated functions and platforms dedicated to pathology, biology and imaging to conduct clinical studies and real-world registries, as well as exploratory research programs. The LYSA has more than 500 members, researchers and medical experts, with a network of about 90 clinical research centers in France, Belgium and Portugal. The LYSA's missions are to promote clinical research, to improve prevention, care, and treatment of patients and to disseminate knowledge about all types of lymphoma. [LYSARC - Experts Recherche Lymphome \(experts-recherche-lymphome.org\)](https://experts-recherche-lymphome.org)

### **LYSARC-LYSA Press contact:**

Aurélien ONNIS, Communication Manager  
[aurelie.onnis@lysarc.org](mailto:aurelie.onnis@lysarc.org)